User banner image
User avatar
  • Ksenia Brusilovskaya

Publications:

Königshofer P; Hofer BS; Brusilovskaya K; Simbrunner B; Petrenko O; Wöran K; Herac M; Stift J; Lampichler K; Timelthaler G; Bauer D; Hartl L; Robl B; Sibila M; Podesser BK; Oberhuber G; Schwabl P; Mandorfer M; Trauner M; Reiberger T, 2021. Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.  Hepatology.

Königshofer P; Brusilovskaya K; Petrenko O; Hofer BS; Schwabl P; Trauner M; Reiberger T, 2021. Nuclear receptors in liver fibrosis.  Biochim Biophys Acta Mol Basis Dis 1867(12):166235

Schwabl P; Hambruch E; Budas GR; Supper P; Burnet M; Liles JT; Birkel M; Brusilovskaya K; Königshofer P; Peck-Radosavljevic M; Watkins WJ; Trauner M; Breckenridge DG; Kremoser C; Reiberger T, 2021. The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model.  Biomedicines 9.

Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P, 2020. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.  United European Gastroenterol J 8(10):1174-1185

Brusilovskaya K; Königshofer P; Schwabl P; Reiberger T, 2019. Vascular Targets for the Treatment of Portal Hypertension.  Semin Liver Dis 39(4):483-501

Königshofer P; Brusilovskaya K; Schwabl P; Reiberger T, 2019. Animal models of portal hypertension.  Biochim Biophys Acta Mol Basis Dis 1865(5):1019-1030

Königshofer P; Brusilovskaya K; Schwabl P; Podesser BK; Trauner M; Reiberger T, 2018. Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats.  J Vis Exp.

Schwabl P; Brusilovskaya K; Supper P; Bauer D; Königshofer P; Riedl F; Hayden H; Fuchs CD; Stift J; Oberhuber G; Aschauer S; Bonderman D; Gnad T; Pfeifer A; Uschner FE; Trebicka J; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Trauner M; Reiberger T, 2018. The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats.  Sci Rep 8(1):9372

Publication list retrieved from NCBI using ImpactPubs

.